Journal ArticleDOI
Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011.
Juan J. Picazo,Jesús Ruiz-Contreras,Juan Casado-Flores,Elisa Giangaspro,Maria-Jesus García-de-Miguel,Teresa Hernández-Sampelayo,Enrique Otheo,Cristina Méndez +7 more
Reads0
Chats0
TLDR
Early data regarding changing fromPCV7 to PCV13 use in the childhood vaccination calendar indicate that reductions in IR of bacteremic pneumonia and meningitis after PCV7 introduction further decreased and there was a reversion of the increase inIR of parapneumonic pneumococcal empyema from 2010-2011, mainly because of reduction in serotype 1 and 19A cases.Abstract:
Background:Differences in invasive pneumococcal disease (IPD) in children are expected after a change from 7-valent pneumococcal conjugate vaccine (PCV7) to 13-valent pneumococcal conjugate vaccine (PCV13). Universal vaccination with PCV7 started in Madrid in November 2006, and it switched to PCV13read more
Citations
More filters
Journal ArticleDOI
Pneumococcal serotype evolution in Western Europe
TL;DR: There is no single ‘19A-like’ serotype emerging across countries and most of the newly emerging non-PCV13 vaccine types are less invasive with a low case-carrier ratio, compared with the time before the introduction of higher valent PCVs.
Journal ArticleDOI
Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012
Agnes Lepoutre,Emmanuelle Varon,Scarlett Georges,F. Dorléans,Claire Janoir,Laurent Gutmann,Daniel Lévy-Bruhl +6 more
TL;DR: Considering the whole 2001-2012 period, the vaccination with PCV7 and PCV13 resulted in a decline in the incidence of IPD in children up to the age of 5 but not in older children and adults.
Journal ArticleDOI
Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
Shalom Ben-Shimol,David Greenberg,Noga Givon-Lavi,Yechiel Schlesinger,Eli Somekh,Shraga Aviner,Dan Miron,Ron Dagan +7 more
TL;DR: After initiation of PCV NIP, a rapid and substantial 2-step IPD reduction was observed in children <5 years, and the serotype-specific rate reduction reflected the sequential introduction ofPCV7/PCV13.
Journal ArticleDOI
Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology
TL;DR: The reported incidence and proportions of CPP among pneumonia cases steadily increased from 1990 to 2012, and changes in the prevalence of serotypes with capacity to invade the pleural space that were not targeted by the 7-valent pneumococcal conjugate vaccine (PCV7).
Journal ArticleDOI
Efficacy of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus That of 7-Valent PCV (PCV7) Against Nasopharyngeal Colonization of Antibiotic-Nonsusceptible Streptococcus pneumoniae
Ron Dagan,Christine Juergens,James Trammel,Scott Patterson,David Greenberg,Noga Givon-Lavi,Nurith Porat,Alejandra Gurtman,William C. Gruber,Daniel A. Scott +9 more
TL;DR: PCV13 will provide protection against ANSP disease that exceeds protection provided by PCV7, and these results suggest that PCV13 has a significant added benefit overPCV7 in reducing carriage of ANSP.
References
More filters
Performance standards for antimicrobial susceptibility testing
TL;DR: The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards.
Journal ArticleDOI
Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine
Tamara Pilishvili,Catherine Lexau,Monica M. Farley,Monica M. Farley,James L. Hadler,Lee H. Harrison,Nancy M. Bennett,Arthur Reingold,Ann Thomas,William Schaffner,Allen S. Craig,Philip J. Smith,Bernard Beall,Cynthia G. Whitney,Matthew R. Moore +14 more
TL;DR: Dramatic reductions in IPD after PCV7 introduction in the United States remain evident 7 years later, and IPD rates caused by serotype 19A and other non-PCV7 types have increased but remain low relative to decreases in PCV 7-type IPD.
Journal ArticleDOI
A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease
Mark C. Enright,Brian G. Spratt +1 more
TL;DR: A pneumococcal multilocus sequence typing scheme and database is developed by sequencing approximately 450 bp fragments of seven housekeeping loci from 295 isolates to provide an allelic profile, or sequence type (ST), and the relatedness between isolates was obtained by constructing a dendrogram from the matrix of pairwise differences between STs.
Journal ArticleDOI
Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study
TL;DR: Despite much serotype replacement, a substantial reduction in invasive pneumococcal disease in young children can be achieved with PCV7 vaccination, with some indirect benefit in older age groups.